
Novartis AG NVS
$ 148.14
1.47%
Annual report 2025
added 03-14-2026
Novartis AG EV - Enterprise Value 2011-2026 | NVS
Annual EV - Enterprise Value Novartis AG
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 53 B | 46.7 B | 39.8 B | 50.5 B | 247 B | 260 B | 253 B | 217 B | 214 B | 202 B | 222 B | 266 B | 227 B | 203 B | 167 B |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 266 B | 39.8 B | 178 B |
EV - Enterprise Value of other stocks in the Biotechnology industry
| Issuer | EV - Enterprise Value | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
1.82 B | - | 2.43 % | $ 254 M | ||
|
Altimmune
ALT
|
329 M | $ 3.45 | 3.29 % | $ 304 M | ||
|
Amgen
AMGN
|
189 B | $ 351.92 | 1.18 % | $ 189 B | ||
|
Amphastar Pharmaceuticals
AMPH
|
1.92 B | $ 19.55 | 0.26 % | $ 914 M | ||
|
I-Mab
IMAB
|
8.28 B | - | - | $ 866 M | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
1.95 B | - | - | $ 40.3 B | ||
|
Genfit SA
GNFT
|
168 B | - | 2.54 % | $ 160 B | ||
|
Autolus Therapeutics plc
AUTL
|
1.11 B | $ 1.4 | 1.82 % | $ 357 M | ||
|
Biophytis SA
BPTS
|
525 M | - | -13.47 % | $ 169 M | ||
|
Ascendis Pharma A/S
ASND
|
849 M | $ 218.41 | -1.57 % | $ 5 B | ||
|
Aytu BioScience
AYTU
|
-15.2 M | $ 2.61 | - | $ 16.4 M | ||
|
Midatech Pharma plc
MTP
|
4.79 M | - | -18.52 % | $ 27.3 M | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
3.41 B | - | -1.52 % | $ 24.7 M | ||
|
Applied Genetic Technologies Corporation
AGTC
|
-9.16 M | - | - | $ 26.5 M | ||
|
ARCA biopharma
ABIO
|
436 M | - | 1052.0 % | $ 415 M | ||
|
Benitec Biopharma
BNTC
|
461 M | $ 11.01 | 0.27 % | $ 453 M | ||
|
Aeterna Zentaris
AEZS
|
5.52 M | - | 5.93 % | $ 314 M | ||
|
AgeX Therapeutics
AGE
|
6.28 M | - | -10.17 % | $ 12.2 K | ||
|
Acorda Therapeutics
ACOR
|
-13.2 M | - | -24.86 % | $ 820 K | ||
|
Albireo Pharma
ALBO
|
417 M | - | -0.23 % | $ 916 M | ||
|
Aileron Therapeutics
ALRN
|
33.1 M | - | 10.36 % | $ 9.8 M | ||
|
Acasti Pharma
ACST
|
24 M | - | 4.01 % | $ 150 M | ||
|
Институт стволовых клеток человека
ISKJ
|
14.1 M | - | - | - | ||
|
Compugen Ltd.
CGEN
|
291 M | $ 2.08 | -0.48 % | $ 194 M | ||
|
Avenue Therapeutics
ATXI
|
-1.23 M | - | -52.27 % | $ 4.45 M | ||
|
Adverum Biotechnologies
ADVM
|
125 M | - | - | $ 86.2 M | ||
|
Acer Therapeutics
ACER
|
38.2 M | - | 2.71 % | $ 14 M | ||
|
Advaxis
ADXS
|
-3.02 M | - | -9.65 % | $ 45.9 M | ||
|
Coherus BioSciences
CHRS
|
335 M | $ 1.59 | 4.28 % | $ 186 M | ||
|
CollPlant Biotechnologies Ltd.
CLGN
|
169 M | $ 0.6 | -1.9 % | $ 6.87 M | ||
|
Cellectis S.A.
CLLS
|
187 M | $ 3.37 | 0.75 % | $ 116 M | ||
|
Ayala Pharmaceuticals
AYLA
|
5.32 M | - | - | $ 7.46 M | ||
|
Cullinan Management
CGEM
|
850 M | $ 12.91 | 1.33 % | $ 778 M | ||
|
Atreca
BCEL
|
94.8 M | - | -11.76 % | $ 5.79 M | ||
|
BioDelivery Sciences International
BDSI
|
445 M | - | -4.8 % | $ 255 M | ||
|
BeiGene, Ltd.
BGNE
|
-720 M | - | 0.49 % | $ 251 B | ||
|
Calithera Biosciences
CALA
|
916 M | - | -10.95 % | $ 876 K | ||
|
Cara Therapeutics
CARA
|
71.1 M | - | -3.03 % | $ 260 M | ||
|
ChemoCentryx
CCXI
|
91.4 M | - | - | $ 3.74 B | ||
|
Bellerophon Therapeutics
BLPH
|
77.1 M | - | -74.18 % | $ 955 K | ||
|
CorMedix
CRMD
|
276 M | $ 6.32 | 1.12 % | $ 455 K | ||
|
Checkpoint Therapeutics
CKPT
|
174 M | - | - | $ 169 M | ||
|
Clovis Oncology
CLVS
|
839 M | - | -7.23 % | $ 13 M | ||
|
Aeglea BioTherapeutics
AGLE
|
-23.2 M | - | - | $ 1.01 B | ||
|
CureVac N.V.
CVAC
|
3.19 B | - | - | $ 867 M | ||
|
Denali Therapeutics
DNLI
|
3.01 B | $ 20.96 | 3.92 % | $ 3.45 B | ||
|
Akero Therapeutics
AKRO
|
2.99 B | - | - | $ 3.67 B | ||
|
Arbutus Biopharma Corporation
ABUS
|
457 M | $ 4.26 | 0.35 % | $ 707 M | ||
|
Akouos
AKUS
|
95.1 M | - | 0.23 % | $ 488 M | ||
|
AIkido Pharma
AIKI
|
22.8 M | - | 1.93 % | $ 17.4 M |